Elapegademase
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.
It is a recombinant enzyme that is administered weekly by intramuscular injection.
Elapegademase may interact with PEGylated drugs.
Elapegademase-lvlr was approved by the U.S. Food and Drug Administration in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.